Association of Raynaud's syndrome with interferons. A meta-analysis

International Angiology

Volumn 31, Issue 5, 2012, Pages 408-413

  Mohokum, M ^a   Hartmann, P ^a   Schlattmann, P ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Cytokines; Interferons; Raynaud disease

Indexed keywords

INTERFERON;

ADVERSE OUTCOME; DRUG SAFETY; HUMAN; IMMUNOTHERAPY; META ANALYSIS; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAYNAUD PHENOMENON; REVIEW;

BLOOD VESSELS; CHI-SQUARE DISTRIBUTION; CYCLOPROPANES; FINGERS; HUMANS; INTERFERONS; LINEAR MODELS; ODDS RATIO; PREVALENCE; RAYNAUD DISEASE; RISK ASSESSMENT; RISK FACTORS;

EID: 84869753678     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Block JA, Sequeira W. Raynaud's phenomenon. Lancet 2001;357:2042-8.
2. Heidrich H. Functional vascular diseases: Raynaud's syndrome, acrocyanosis and erythromelalgia. Vasa 2010;39:33-41.
3. Koszewicz M, Gosk-Bierska I, Bilinska M, Podemski R, Budrewicz S, Adamiec R et al. Autonomic dysfunction in primary Raynaud's phenomenon. Int Angiol 2009;28:127-31.
4. Fraenkel L. Raynaud's phenomenon: epidemiology and risk factors. Curr Rheumatol Rep 2002;4:123-8.
5. Schapira D, Nahir AM, Hadad N. Interferon-induced Raynaud's syndrome. Semin Arthritis Rheum 2002;32:157-62.
6. Guillot B, Blazquez L, Bessis D, Dereure O, Guilhou JJ. A prospective study of cutaneous adverse events induced by low-dose alpha-interferon treatment for malignant melanoma. Dermatology 2004;208:49-54. (Pubitemid 38142334)
7. Kotter I, Hamuryudan V, Ozturk ZE, Yazici H. Interferon therapy in rheumatic diseases: state-of-the-art 2010. Curr Opin Rheumatol 2010;22:278-83.
8. Akriviadis EA, Xanthakis I, Navrozidou C, Papadopoulos A. Prevalence of cryoglobulinemia in chronic hepatitis C virus infection and response to treatment with interferon-alpha. J Clin Gastroenterol 1997;25:612-8. (Pubitemid 28051597)
9. Creutzig A, Caspary L, Freund M. The Raynaud phenomenon and interferon therapy. Ann Intern Med 1996;125:423.
10. Schwarzer G. Meta-analysis with R. 1.5-0. Fixed and random effects meta-analysis. Functions for tests of bias, forest and funnel plot [computer software].
11. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58. (Pubitemid 34746062)
12. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60. (Pubitemid 37088507)
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. (Pubitemid 17189972)
14. Schlattmann P. Medical applications of finite mixture models. Berlin, Heidelberg: Springer-Verlag; 2009.
15. Galbraith RF. Graphical display of estimates having differing standard errors. Technometrics 1988;30:271-81. (Pubitemid 20649623)
16. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34. (Pubitemid 27387172)
17. Thompson SG. How should meta-regression analyses be undertaken and interpreted Statistics in Medicine 2002;21:1559-73. (Pubitemid 34746063)
18. Lumley T. Meta-analysis [computer software].
19. Schlattmann P. Finite mixture models and metaanalysis tools - based on C.A.MAN. 0.64 ed2008 [computer software].
20. Niederle N, Kurschel E, Schmidt CG. [Biological effect of recombined leukocyte alpha-2-interferon in metastasizing colorectal cancers]. Dtsch Med Wochenschr 1984;109:779-82.
21. Polisson RP, Gilkeson GS, Pyun EH, Pisetsky DS, Smith EA, Simon LS. A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels. J Rheumatol 1996;23:654-8. (Pubitemid 26132850)
22. Tothova E, Kafkova A, Stecova N, Fricova M, Guman T, Svorcova E. Immune-mediated complications during interferon alpha therapy in chronic myelogenous leukemia. Neoplasma 2002;49:91-4. (Pubitemid 34493667)
23. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.
24. Weinrich MC, Maricq HR, Keil JE, McGregor AR, Diat F. Prevalence of Raynaud phenomenon in the adult population of South Carolina. J Clin Epidemiol 1990;43:1343-9.
25. De Angelis R, Salaffi F, Grassi W. Raynaud's phenomenon: prevalence in an Italian population sample. Clin Rheumatol 2006;25:506-10. (Pubitemid 44137624)
26. Suter LG, Murabito JM, Felson DT, Fraenkel L. The incidence and natural history of Raynaud's phenomenon in the community. Arthritis Rheum 2005;52:1259-63. (Pubitemid 40530134)
27. Kruit WH, Eggermont AM, Stoter G. Interferon-alpha induced Raynaud's syndrome. Ann Oncol 2000;11:1501-2.
28. Zeidman A, Dicker D, Mittelman M. Interferon-induced vasospasm in chronic myeloid leukaemia. Acta Haematol 1998;100:94-6. (Pubitemid 28482570)
29. Blaheta RA, Scholz M, Hailer NP, Bereiter-Hahn J, Encke A, Markus BH. Adhesion and penetration properties of human lymphocytes acting on allogeneic vascular endothelial cells. Immunology 1994;81:538-45. (Pubitemid 24246501)
30. Chung MS, Gong HS, Baek GH. Prevalence of Raynaud's phenomenon in patients with idiopathic carpal tunnel syndrome. J Bone Joint Surg Br 1999;81:1017-9.
31. Maricq HR, Carpentier PH, Weinrich MC, Keil JE, Palesch Y, Biro C et al. Geographic variation in the prevalence of Raynaud's phenomenon: a 5 region comparison. J Rheumatol 1997;24:879-89. (Pubitemid 27223622)